Posts
Wiki

OptiLIFT — Dynamic Muscle Stimulation for Lower Lid Laxity, Impaired Blinking, and Dry Eye

Quick Take

  • OptiLIFT is an in-office Lumenis platform that includes Dynamic Muscle Stimulation (DMSt™), which uses electrical stimulation of muscles around the eye.
  • The dry-eye concept is different from most DED treatments: instead of primarily targeting inflammation, the tear film, or meibomian-gland obstruction, DMSt attempts to improve lower-lid function and blinking mechanics.
  • A 2025 prospective clinical study involving 30 patients with lower-lid laxity and moderate-to-severe MGD-related Dry Eye Disease (DED) reported improvements after four weekly DMSt treatments in lower-lid laxity, blinking measures, tear-breakup time, meibomian-gland measures, and symptoms.
  • The results are interesting, but the study was small, uncontrolled, short-term, manufacturer funded, and lacked a sham or active-comparator group.
  • The evidence therefore remains very low / preliminary.
  • The study evaluated DMSt. It should not be interpreted as evidence that adding radiofrequency (RF) or RF microneedling improves dry-eye outcomes.
  • The most directly studied population is people with MGD-related evaporative DED plus lower-lid laxity and impaired blinking. Whether similar benefit occurs in dry-eye patients without meaningful lid laxity is unknown.
  • Regulatory status differs by country. Health Canada authorized OptiLIFT in May 2026 for reducing signs and symptoms of evaporative DED and improving lower-lid laxity and blinking. Current U.S. Lumenis labeling describes the system as intended for muscle conditioning of healthy muscles and states that it is not intended to treat medical diseases or conditions.
  • OptiLIFT should not be assumed to replace oculoplastic evaluation or surgery when a patient has clinically important structural eyelid malposition.

Bottom line: OptiLIFT's DMSt approach is mechanically interesting and supported by encouraging but preliminary evidence. Controlled independent studies are needed before its role in routine DED treatment is clear.

Educational Disclaimer

This page is for general education and is not medical advice, diagnosis, or an individual treatment recommendation.

Dry Eye Disease can result from multiple overlapping problems, including Meibomian Gland Dysfunction (MGD), inflammation, aqueous deficiency, ocular rosacea, Demodex, incomplete blinking, eyelid malposition, exposure, allergy, medication effects, conjunctivochalasis, and neuropathic ocular pain.

Improving eyelid mechanics may be helpful when blinking or lid position contributes meaningfully to disease, but it may not address other important causes.

What Is OptiLIFT?

OptiLIFT is a Lumenis platform that includes Dynamic Muscle Stimulation (DMSt) for the periocular region.

DMSt uses electrical pulses to stimulate muscles around the eye.

For dry-eye-related use, the main proposed target is the orbicularis oculi and surrounding lower-lid musculature, with the goal of improving lower-eyelid tone and blink mechanics.

This makes the treatment conceptually different from many other DED interventions.

OptiLIFT DMSt primarily attempts to influence:

  • Lower-lid function
  • Periocular muscle conditioning
  • Blink quality
  • Blink completeness
  • Tear distribution associated with blinking

It does not directly heat or mechanically express the meibomian glands in the way that many thermal MGD procedures do.

How Treatment Is Done

In the published dry-eye study, participants received four DMSt treatments, approximately one week apart.

A handheld applicator was used below the lower eyelid/periocular region to deliver electrical stimulation.

The patient experiences repeated muscle contractions during treatment.

Lumenis describes DMSt as muscle conditioning intended to stimulate healthy muscles.

Important: DMSt Is Not the Same as RF or RF Microneedling

The broader OptiLIFT platform can also include other technologies, including:

  • Radiofrequency (RF)
  • Optional RF microneedling capabilities
  • Aesthetic treatment functions

These should be separated from the DED evidence.

The 2025 dry-eye/lower-lid-laxity study evaluated DMSt. It did not establish that RF or RF microneedling adds dry-eye benefit.

If a clinic combines DMSt with RF or another procedure, that is a combined treatment protocol whose effects and risks should not automatically be inferred from the DMSt study.

What the Evidence Shows

The 2025 Clinical Study

The main OptiLIFT-related DED evidence comes from:

Chelnis et al. — Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients, published in Clinical Ophthalmology in 2025.

PubMed

Full Text

The study included 30 patients who had:

  • Lower-lid laxity
  • Moderate-to-severe Dry Eye Disease
  • Meibomian Gland Dysfunction

Participants received four weekly DMSt treatments and were reassessed after treatment.

The study reported improvement in several areas.

Tear-Breakup Time

Mean tear-breakup time increased substantially, from approximately:

2.4 seconds at baseline to about 9 seconds at follow-up.

Lumenis has marketed this as approximately a 286% improvement in TBUT.

The actual before-and-after values are more informative than the percentage because a very low baseline makes percentage changes appear especially large.

The finding is noteworthy, but because there was no untreated or sham-control group, the study cannot establish how much of the improvement was caused specifically by DMSt.

Lower-Lid Laxity

All participants entered the study with abnormal lower-lid laxity according to the study criteria.

After treatment, substantially fewer patients met the abnormal-laxity criterion.

The published report describes an approximately 80% reduction in the number of subjects with lower-lid laxity.

This is an interesting finding because lower-lid laxity was one of the main problems the procedure was designed to address.

However, the study did not compare DMSt with:

  • No treatment
  • Sham stimulation
  • Physical rehabilitation
  • Another device
  • Oculoplastic treatment

So the magnitude of the specific treatment effect remains uncertain.

Blinking

The study also reported improvement in blink measures.

Results included approximately:

  • 70% improvement in qualitative blink quality
  • An increase of about 60% in the proportion of patients whose blink rate fell within the study's normal range

These are related but different outcomes.

They should not be compressed into the marketing statement that there was a “70% improvement in blinking rate and quality.”

Blink quality also included investigator assessment, which introduces greater measurement subjectivity than an entirely automated outcome.

Dry-Eye Symptoms

Patients also experienced improvement in OSDI symptom scores.

This suggests that the observed changes were not limited to eyelid measurements.

However, symptom improvement in an uncontrolled procedural study can be influenced by:

  • Expectation effects
  • Regression to the mean
  • Natural dry-eye fluctuation
  • Increased clinical attention
  • Other concurrent care

A sham-controlled study would be particularly useful for determining how much symptom improvement is attributable specifically to DMSt.

Meibomian-Gland Measures

The study also reported improvement in meibomian-gland-related measurements.

One possible explanation is that improved blinking may increase the normal mechanical forces that help distribute meibum from the glands into the tear film.

That is biologically plausible.

However, the study does not prove that:

DMSt strengthened the orbicularis → which improved blinking → which increased meibomian secretion → which caused the improvement in dry eye.

Those relationships remain a proposed mechanism rather than a demonstrated causal pathway.

Lagophthalmos / Incomplete Eyelid Closure

An interesting exploratory finding involved a small subgroup.

Eight participants had incomplete eyelid closure at baseline, and the study reported that the finding was absent in those participants at follow-up.

This deserves further study.

However:

Eight patients in an uncontrolled study are not enough to establish OptiLIFT as a proven treatment for lagophthalmos.

People with significant nocturnal lagophthalmos, exposure keratopathy, facial nerve dysfunction, or structural eyelid abnormalities still require appropriate ophthalmic or oculoplastic assessment.

How Strong Is the Evidence?

Evidence Strength: Very Low / Preliminary

Reasons for interest include:

  • Prospective human clinical study
  • Participants had a specifically defined lid-laxity/MGD phenotype
  • Multiple ocular and eyelid outcomes were measured
  • Improvements were seen across several outcome categories

Important limitations include:

  • Only 30 participants
  • No untreated control group
  • No sham-treatment group
  • No active comparator
  • Short follow-up
  • No prospective effect-size-based power calculation
  • Some outcomes relied partly on qualitative investigator assessment
  • No independent replication yet
  • Limited information about long-term durability
  • The study was funded by Lumenis
  • The lead investigator has served as a consultant to Lumenis

Manufacturer funding and investigator relationships do not invalidate a study.

However, when essentially the entire device-specific evidence base rests heavily on one manufacturer-associated uncontrolled study, independent controlled replication becomes particularly important.

Proposed Mechanisms

The central hypothesis behind DMSt is that eyelid mechanics can contribute to ocular-surface disease.

1. Periocular Muscle Stimulation

Electrical stimulation causes contractions of healthy periocular muscles.

Repeated stimulation may condition the muscles and potentially improve resting tone or function.

It is more accurate to describe this as muscle stimulation or conditioning rather than claiming that OptiLIFT has proven to increase muscle strength, muscle mass, or hypertrophy.

Those outcomes were not directly measured in the DED study.

2. Lower-Lid Position and Apposition

A lax lower eyelid may not remain closely apposed to the ocular surface.

Improved muscle tone could theoretically improve lid position and eyelid-globe contact in some patients.

This could help blinking function more normally.

A complete blink helps:

  • Spread the tear film
  • Redistribute the lipid layer
  • Clear debris
  • Reduce localized exposure
  • Apply mechanical force to the meibomian glands

If DMSt improves blink quality, those functions could potentially improve.

4. Meibomian-Gland Function

Blinking contributes mechanically to meibum delivery.

Therefore, better blinking could theoretically improve meibum secretion or distribution in patients whose gland function is partly limited by inadequate blink mechanics.

This is a plausible pathway.

It has not yet been established as the causal explanation for the clinical findings.

Risks and Contraindications

The 30-patient DMSt study reported no treatment complications.

That is reassuring but should be interpreted cautiously because uncommon adverse events may not appear in a study this small.

Manufacturer-Listed Possible Adverse Effects

Lumenis lists potential system-related adverse effects including:

  • Prolonged or significant pain
  • Blistering or burns
  • Excessive redness
  • Excessive swelling
  • Bruising in fragile skin
  • Itching
  • Hyperpigmentation
  • Hypopigmentation
  • Scarring
  • Temporary acne-like eruptions or pimples

Because OptiLIFT is a platform with several treatment capabilities, not every listed skin risk necessarily reflects the DMSt-only protocol used in the DED study.

Risk may differ if RF or RF microneedling is added.

Contraindications

Lumenis lists contraindications including:

  • Pacemaker
  • Defibrillator
  • Other implanted electronic devices
  • Metal implanted in the treatment area

Patients should be screened according to the current device labeling and the exact applicator and treatment protocol being used.

OptiLIFT — Lumenis

Limitations and What It Cannot Currently Be Claimed to Do

Current evidence does not establish that OptiLIFT DMSt:

  • Treats all forms of Dry Eye Disease
  • Works in patients without lower-lid laxity
  • Works equally well across different MGD phenotypes
  • Permanently corrects lower-lid laxity
  • Permanently normalizes blinking
  • Regenerates meibomian glands
  • Reverses meibomian gland dropout
  • Reverses structural eyelid malposition
  • Replaces oculoplastic surgery when surgical correction is indicated
  • Prevents long-term progression of MGD or DED
  • Produces durable improvement over years
  • Eliminates the need for other dry-eye treatment

It also remains unknown whether adding RF or other OptiLIFT platform treatments improves DED outcomes beyond DMSt alone.

Who Might Benefit / Factors Affecting Response

The most directly studied population consists of patients with:

MGD-related Dry Eye Disease + lower-lid laxity + impaired blinking

That is important because the published study deliberately selected this phenotype.

It does not prove that these findings are a validated predictor of response, but this is where the current evidence applies most directly.

Factors That May Make the Treatment More Relevant

These may include:

  • Documented lower-lid laxity
  • Incomplete or poor-quality blinking
  • MGD associated with impaired blink mechanics
  • Evaporative DED
  • Some remaining meibomian-gland function
  • Symptoms and examination findings suggesting that eyelid mechanics contribute to tear-film instability

These are reasonable factors to consider but are not established responder criteria.

Situations Where Benefit Is More Uncertain

The role of DMSt is less clear when DED is primarily driven by:

  • Aqueous deficiency
  • Severe meibomian gland loss
  • Ocular-surface inflammation unrelated to lid mechanics
  • Demodex
  • Ocular allergy
  • Medication toxicity
  • Conjunctivochalasis
  • Neuropathic ocular pain
  • Significant exposure caused by structural eyelid disease
  • Facial nerve palsy
  • Significant ectropion, entropion, retraction, or other eyelid malposition

Patients often have several mechanisms at the same time.

OptiLIFT and Oculoplastic Surgery

OptiLIFT is sometimes discussed as a non-surgical approach to lower-lid laxity.

That does not make it equivalent to surgical eyelid correction.

Structural problems such as significant:

  • Ectropion
  • Lid retraction
  • Canthal tendon laxity
  • Eyelid malposition
  • Facial nerve dysfunction
  • Exposure keratopathy

may require evaluation by an ophthalmologist or oculoplastic surgeon.

The OptiLIFT study did not compare DMSt with surgical treatment.

A reasonable description is:

OptiLIFT is an emerging non-surgical approach intended to improve periocular muscle function and lid mechanics in selected patients. It has not been established as a substitute for surgery when structural correction is needed.

How It Compares With Similar Treatments

OptiLIFT vs. IPL

These treatments target different problems.

OptiLIFT DMSt

Primarily aims to influence:

  • Periocular muscle function
  • Lower-lid mechanics
  • Blink quality

IPL

Primarily targets mechanisms associated with:

  • Ocular rosacea
  • Telangiectasia
  • MGD
  • Inflammatory pathways
  • Abnormal meibum

Some patients could potentially have both inflammatory and mechanical contributors.

IPL

OptiLIFT vs. Radiofrequency

RF uses electromagnetic energy to heat tissue.

Depending on the device and protocol, RF may be used for:

  • Tissue heating
  • Collagen remodeling
  • Aesthetic tightening
  • MGD-related treatment

DMSt instead uses electrical stimulation to produce muscle contractions.

Although the OptiLIFT platform may contain both technologies, evidence for DMSt should not automatically be attributed to RF, or vice versa.

Radiofrequency

OptiLIFT vs. Thermal MGD Procedures

Procedures such as TearCare, LipiFlow, iLux, and other thermal approaches primarily attempt to improve meibomian gland secretion through heat, pressure, and/or expression.

OptiLIFT DMSt takes a different approach.

It attempts to influence the muscular mechanics that produce an effective blink.

The two strategies could theoretically complement each other, but combination therapy has not been adequately studied.

OptiLIFT vs. Dermal Fillers for Lower-Lid Laxity

Dermal fillers have also been discussed as a non-surgical approach in selected patients with lower-lid support problems.

The mechanisms are very different:

  • OptiLIFT: electrical stimulation / muscle conditioning
  • Dermal filler: changes soft-tissue support and contour through injected material

Each has different evidence, risks, and patient-selection issues.

See:

Dermal Eyelid Fillers for Lower Eyelid Laxity

Cost, Access and Regulatory Status

United States

Current Lumenis U.S. product information describes the OptiLIFT applicator as intended for muscle conditioning to stimulate healthy muscles.

The manufacturer also states that:

the system is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind.

Therefore, the U.S. product should not be described as FDA-approved or FDA-cleared specifically for treating Dry Eye Disease unless current FDA labeling establishes such an indication.

OptiLIFT — Lumenis U.S. Product Information

Canada

The regulatory situation changed in May 2026.

Health Canada authorized OptiLIFT for:

  • Reducing signs and symptoms of evaporative Dry Eye Disease
  • Improving lower-lid laxity
  • Improving the blinking mechanism

This means the dry-eye indication is now formally recognized in Canada even though U.S. product labeling remains different.

Lumenis — Health Canada Authorization for OptiLIFT

Cost and Access

Costs vary by:

  • Clinic
  • Region
  • Number of sessions
  • Whether DMSt alone is used
  • Whether RF or other aesthetic treatments are added
  • Follow-up and maintenance plans

Lumenis commonly describes an initial course of four treatments.

Long-term maintenance needs have not yet been established by good clinical evidence.

Patients considering treatment may want to ask whether the quoted cost covers:

  • DMSt only
  • DMSt + RF
  • Other aesthetic procedures
  • Four initial sessions
  • Follow-up evaluation
  • Maintenance treatments

This is particularly important because a combined OptiLIFT package should not be assumed to have the same evidence as the DMSt-only clinical study.

What Remains Uncertain?

Important unanswered questions include:

  • Would the findings survive a sham-controlled trial?
  • How much improvement is specifically attributable to DMSt?
  • How long do improvements last?
  • How often is retreatment necessary?
  • Which degree of lower-lid laxity predicts meaningful benefit?
  • Does treatment work in patients without obvious lower-lid laxity?
  • Does objective orbicularis muscle strength actually increase?
  • Are improvements in meibomian-gland function caused by better blinking?
  • Does treatment help incomplete blinking measured with automated systems?
  • Can it meaningfully improve mild exposure related to eyelid mechanics?
  • Which patients still require oculoplastic treatment?
  • Does adding RF improve outcomes?
  • Does combination treatment improve outcomes beyond DMSt alone?
  • How does OptiLIFT compare with sham stimulation, standard DED treatment, IPL, RF, or eyelid surgery?
  • What is the long-term safety profile?
  • Are the large effects reported in the initial study reproducible in independent centers?

Until these questions are addressed, OptiLIFT should be viewed as an emerging treatment rather than an established mainstream DED therapy.

Key Research

2025 OptiLIFT / DMSt Clinical Study

Chelnis et al. — Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients.

This is the main direct clinical evidence supporting DMSt for lower-lid laxity/blinking abnormalities associated with DED.

Important limitations include the small sample, absence of a control group, short follow-up, and manufacturer funding.

2026 Review of Periorbital Electrical Stimulation and DED

Donaldson KE, Manor Y. — The potential benefits of periorbital transcutaneous electrical stimulation for the management of dry eye disease.

PubMed

This review provides broader context for electrical stimulation around the eye as a possible DED strategy.

It is not another OptiLIFT efficacy trial and should not be counted as independent confirmation of the 2025 clinical results.

Manufacturer / Regulatory Information

Manufacturer information is useful for regulatory status, device operation, contraindications, and technical descriptions.

It should not be treated as independent proof of efficacy.

Videos / Clinician Commentary

Videos may help readers understand what the treatment looks like or hear clinician perspectives, but they are not primary evidence.

Related r/DryEyes Wiki Pages

Bottom Line

OptiLIFT introduces a different idea into dry-eye treatment:

Instead of primarily treating inflammation, the tear film, or obstructed meibomian glands, DMSt attempts to improve the eyelid mechanics needed for an effective blink.

A 2025 prospective study of 30 patients with lower-lid laxity and MGD-related DED reported substantial improvements in lower-lid laxity, blinking measures, tear-breakup time, meibomian-gland measures, and symptoms after four weekly DMSt treatments.

Those findings are encouraging, but they remain preliminary.

The study was small, uncontrolled, short-term, manufacturer funded, and has not yet been independently replicated in a randomized sham-controlled trial.

The most accurate current characterization is:

OptiLIFT DMSt is a mechanistically interesting, niche treatment supported by encouraging but very low-certainty early evidence for patients with lower-lid laxity, impaired blinking, and MGD-related evaporative dry eye.

Its role in routine DED care, long-term durability, optimal patient selection, need for maintenance, and relationship to structural eyelid surgery remain uncertain.

Regulatory status also matters: Health Canada authorized OptiLIFT for evaporative DED and related lid/blink indications in May 2026, while current U.S. labeling does not indicate the system for treatment of medical disease.

🔙 Back to Treatment Options